1996
DOI: 10.1016/0167-7799(96)10054-8
|View full text |Cite
|
Sign up to set email alerts
|

Hematopoietic cell culture therapies (Part II): clinical aspects and applications

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
20
0

Year Published

1997
1997
2012
2012

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 34 publications
(20 citation statements)
references
References 51 publications
0
20
0
Order By: Relevance
“…We chose MNCs for this study because of their significant potential for clinical use, which may be equal or greater to that of CD34 + cells (McAdams et al, 1996). In comparing the performance of PB MNCs versus CB MNCs, we noticed that, in general, both types of cells responded similarly to culture pH.…”
Section: Discussionmentioning
confidence: 99%
“…We chose MNCs for this study because of their significant potential for clinical use, which may be equal or greater to that of CD34 + cells (McAdams et al, 1996). In comparing the performance of PB MNCs versus CB MNCs, we noticed that, in general, both types of cells responded similarly to culture pH.…”
Section: Discussionmentioning
confidence: 99%
“…This, in turn, will require more precise understanding of the conditions required to optimize expansion of the population of interest as well as knowledge of the effects of altered conditions on this endpoint in both small-and large-scale culture systems. Because the utility of hematopoietic stem cell (HSC) transplants is well established in clinical medicine (Aglietta et al, 1998;Hoffman, 1999;McAdams et al, 1996;Srour et al, 1999) and the problems due to inadequate HSC numbers are well defined, we have chosen to focus on ex vivo HSC expansion as an initial process for the analysis of interacting cytokine dose effects on stem cell fate decisions in vitro.…”
Section: Introductionmentioning
confidence: 99%
“…As evidenced by recent clinical trials (Brugger et al, 1995), ex vivo expanded hematopoietic cells offer great promise for the reconstitution of in vivo hematopoiesis in immunocompromised patients who have undergone chemotherapy. Other potential applications for ex vivo expansion include production of cycling stem and progenitor cells for gene therapy, expansion of dendritic cells for immunotherapy, and production of red blood cells and platelets for transfusions (McAdams et al, 1996b).…”
Section: Introductionmentioning
confidence: 99%